ICON Goes Local As China CRO Market Heats Up
This article was originally published in PharmAsia News
Acquisition of BeijingWits will boost ICON’s clinical trial capabilities in China and the Asia Pacific region.
You may also be interested in...
As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market
Spurred By Demand For Global And Regional Trials In India, China And Japan, ICON Charts Asia Growth Strategy
SINGAPORE - Malcolm Burgess, Executive VP Asia Pacific with Ireland-headquartered ICON Plc - one of the fastest growing contract research organizations in Asia - expresses satisfaction that over the past seven years he could develop a close bonding with his 600 plus staffers based in the medium-sized cities of Chennai and Thiruvananthapuram at the southern tip of India